Occurrence of Osteoporosis in COPD Patients- A Comparative Study with Age & Sex Matched Control

Authors
Dr Fatima Mamnoon, Dr Abhijeet Khandelwal, Dr Pralhad Prabhudesai
Lilavati Hospital & Research Centre, Mumbai
Corresponding Author
Dr Fatima Mamnoon
Department of Pulmonary Medicine, Grant Medical College, Mumbai
Email: f87.mamnoon@gmail.com, Mobile No. 9820230241

ABSTRACT
Introduction: Chronic Obstructive Pulmonary Disease (COPD) has been found to be associated with a variety of systemic manifestations and reduced bone mineral density being one of them. Due to scarcity of available Indian data, there is a need to evaluate the problem of osteoporosis in Indian population.

Methods: This prospective observational study was conducted with the objectives of studying the occurrence of osteoporosis in COPD patients as compared to age-sex matched controls and to assess the co-relation of osteoporosis with the severity of COPD. 60 COPD (35 males & 25 females) cases, age & sex matched 60 control were classified. GOLD criteria 2013 was used to grade severity. Detailed clinical history & examination, blood investigations, spirometry & DEXA for bone density measurement was done.

Results: Among 60 COPD patients, 37 had osteoporosis (40.5% females, 59.45% males), 22 had osteopenia. As apposed, only 11.6% & 68.3% control group patients had osteoporosis & osteopenia respectively. We found Lumbar spine osteoporosis to be more common. 22.2% moderate, 96% severe & 85.7% very severe COPD patients had osteoporosis, which was statistically significant.

Conclusion: COPD patients are at a greater risk for osteoporosis when compared to age-sex matched control group patients. This risk increased with the severity of COPD.

Keywords: COPD, Osteoporosis, spirometry, DEXA.

INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable disease, is characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and co-morbidities contribute to the overall severity in individual patients. [1]

The prevalence of COPD in the adult population ranges between 4% and 10% and World Health Organization projections predict that COPD-related mortality and disability will continue to increase worldwide during the next two decades. [2] COPD has been found to be associated with a variety of systemic manifestations, and amongst these, reduced bone mineral density (BMD) has been recognized as one of the systemic effects of
COPD irrespective of the stage of the disease. As there is a predicted worldwide increase in COPD, with subsequent bone problems such as fractures, identification of such patients with a high risk of osteoporosis is essential. Increased awareness is therefore essential in order to diagnose and treat bone loss to reduce the risk of fractures.

The prevalence of osteoporosis in COPD patients is 36% to 60% and that of osteopenia is 35% to 72%. Moreover, COPD patients have a higher risk of osteoporosis as compared to healthy subjects.

According to World Health organization, osteopenia (T-score between −1.0 and −2.5) and osteoporosis (T-score below −2.5) are conditions characterized by a decrease in bone mass and density, leading to fragility of the bone.

One of the most obvious causes of osteoporosis in these patients is treatment with glucocorticoids, various studies done on the role of inhaled corticosteroids (ICS) with osteoporosis in COPD patients concluded that, ICS does not aggravate bone mineral loss in COPD patients. Even in glucocorticoid naïve patients, BMD is found to be lower than in age-matched control subjects, and consequently, fracture risk higher.

Other risk factors for developing osteoporosis in COPD are smoking, aging, female sex, low body mass index, decreased physical activities and systemic inflammation.

There are a lot of studies available describing the prevalence of osteoporosis in COPD in the western literature but, there are hardly any studies available that has studied this problem in Indian population. to improve their quality of life by appropriate preventive strategies.

This study was conducted with the aim of assessing osteoporosis in a sample of COPD patients in comparison with the clinical and functional characteristics of osteoporotic, osteopenic, and normal-bone-mass patients which will be helpful to improve their quality of life by appropriate preventive strategies.

**MATERIAL & METHODS**

The subjects of this case-control study was clinically stable COPD patients (cases). The control group consisted of healthy volunteers with age and sex matched, coming for their routine health check-up in our tertiary care center. The duration of our study was 18 months. This study was conducted with the aim of assessing the occurrence of osteoporosis in COPD patients as compared to age-sex matched controls along with correlating it with the severity of COPD. The degree of airflow limitation was assessed by spirometry and stratified in accordance with the Global Initiative for Chronic Obstructive Pulmonary Disease. We included subjects of both gender and of age group in between 50 to 86 years (60 in each, COPD and the control group) fulfilling inclusion criteria.

1. Diagnosed case of COPD on the basis spirometry criteria (patients with post-bronchodilation FEV1/FVC <0.7) and also those who had a history of exposure to risk factors.
2. Clinically stable for the last 4 weeks (no exacerbations).
3. Healthy controls with osteoporosis based on T-score and without vertebral fractures, as well as healthy controls without osteoporosis based on T-score and without vertebral fractures.

Patients excluded from the study were those with history of respiratory disease other than COPD, chest surgery, Bone disease or Osteomalacia, Chronic Liver Disease, Rheumatoid Arthritis, Heart Failure(ejection fraction <45%), Renal Failure and History of steroid intake among control group. Demographic data of the patients were noted. Number of COPD exacerbations in the last 1 year, history of smoking, presence of comorbidities Documented evidence of control group patients having no respiratory complains or disease was noted.BMD at the lumbar spine (L1-L4), the bilateral femoral neck and whole body was measured by Dual X-Ray Absorptiometry (Lunar prodigy). BMD is reported as an absolute
value (g/cm$^2$) and a T score, which represents the number of standard deviations from a young, sex- and ethnic group-specific reference mean. Cases and Control Subjects, both were grouped according to the WHO criteria, and diagnosed as osteoporotic, osteopenic, or normal bone mass according to T-score for BMD. The lowest T-score at either region determined the diagnosis. Thus, if the T-score at either region was below −2.5, the individual was diagnosed as having osteoporosis. If the lowest T-score at either region was between −2.5 and −1.0 the subject was diagnosed with osteopenia. If hip, lumbar spine and whole body T-score was above −1.0 the study subject was grouped as having normal bone mass. The incidence of osteoporosis/osteopenia occurring in COPD patients was assessed and compared to the control group (healthy volunteers). Informed written consent from all subjects who participates in the study. Samples were taken by using universal sample technique.

**RESULTS**

As seen in table 1 and 2 the study population (cases and control group) was age and sex matched

| Gender | COPD (%) | Control (%) | Total |
|--------|----------|-------------|-------|
| Female | 25 (41.7%) | 25 (41.7%) | 50 (41.7%) |
| Male   | 35 (58.3%) | 35 (58.3%) | 70 (58.3%) |
| Total  | 60 (100%)  | 60 (100%)  | 120 (100%) |

| Variables | Group | Mean | SD | Median | IQR | t-value | p-value |
|-----------|-------|------|----|--------|-----|---------|---------|
| Age (Yrs) | COPD  | 66.82 | 8.06 | 66.00 | 11.75 | 0.011   | 0.991   |
|           | Control | 66.82 | 8.06 | 67.00 | 11.75 | Difference is not significant |

**Table 3:** Correlation between Gender & Lumbar (AP spine) Bone Mineral Density (T-score) among COPD patients.

| Gender | BMD t-score (lumbar spine) | Total |
|--------|---------------------------|-------|
|        | Osteoporosis | Osteopenia | Normal |
| Female | 14 (56%) | 11 (44%) | 0 (0%) | 25 (100%) |
| Male   | 20 (57.1%) | 14 (40%) | 1 (2.9%) | 35 (100%) |
| Total  | 34 (56.7%) | 25 (41.7%) | 1 (1.7%) | 60 (100%) |

Pearson Chi-Square

| Value | Df | p-value | Association |
|-------|----|---------|-------------|
| 0.774 | 2  | 0.679   | Not significant |

**Table 4:** Correlation between Gender & Dual Femur (neck) Mineral Density (T-score) among COPD patients.

| Gender | BMD t-score (Dual femur-neck) | Total |
|--------|-------------------------------|-------|
|        | Osteoporosis | Osteopenia | Normal |
| Female | 5 (20.0%) | 19 (76.0%) | 1 (4.0%) | 25 (100.0%) |
| Male   | 15 (42.9%) | 14 (40.0%) | 6 (17.1%) | 35 (100.0%) |
| Total  | 20 (33.3%) | 33 (55.0%) | 7 (11.7%) | 60 (100.0%) |

Pearson Chi-Square

| Value | Df | p-value | Association |
|-------|----|---------|-------------|
| 7.881 | 2  | 0.019   | Significant |
Table 5: Correlation between Gender & Whole Body Mineral Density (T-score) among COPD patients.

| Gender      | Osteoporosis | Osteopenia | Normal | Total |
|-------------|--------------|------------|--------|-------|
| Female (%)  | 2 (8.0%)     | 19 (76.0%) | 4 (16.0%) | 25 (100.0%) |
| Male (%)    | 8 (22.9%)    | 18 (51.4%) | 9 (25.7%) | 35 (100.0%) |
| Total (%)   | 10 (16.7%)   | 37 (61.7%) | 13 (21.7%) | 60 (100.0%) |

Chi-Square Tests
- Value: 3,994
- Df: 2
- p-value: 0.136
- Association is Not significant

Tables 3-5 show that males were more osteoporotic than females. Overall 23/35 (65.71%) males and 14/25 (56%) females were diagnosed with osteoporosis. The association of Gender with osteoporosis was not statistically significant.

Table 6: Lumbar spine Bone Mineral Density among cases and control.

| BMD t-score (lumbar spine) | Group | Total |
|---------------------------|-------|-------|
|                          | COPD  | Control | Total |
| Osteoporosis             | 34 (56.7%) | 5 (8.3%) | 39 (32.5%) |
| Osteopenia               | 25 (41.7%) | 38 (63.3%) | 63 (52.5%) |
| Normal                   | 1 (1.7%) | 17 (28.3%) | 18 (15.0%) |
| Total                    | 60 (100.0%) | 60 (100.0%) | 120 (100.0%) |

Chi-Square Tests
- Value: 38.469
- Df: 2
- p-value: 4.43E-09
- Association is Significant

Table 7: Dual Femur (neck) Bone Mineral Density among the cases and control.

| BMD t-score (Dual femur-neck) | Group | Total |
|-------------------------------|-------|-------|
|                              | COPD  | Control | Total |
| Osteoporosis                 | 20 (33.3%) | 2 (3.3%) | 22 (18.3%) |
| Osteopenia                   | 33 (55.0%) | 34 (56.7%) | 67 (55.8%) |
| Normal                       | 7 (11.7%) | 24 (40.0%) | 31 (25.8%) |
| Total                        | 60 (100.0%) | 60 (100.0%) | 120 (100.0%) |

Chi-Square Tests
- Value: 24.065
- Df: 2
- p-value: 5.95E-06
- Association is Significant
Table 8: Whole Body Bone Mineral Density among cases and control.

| T-score (Whole body) | Group | COPD       | Control  | Total  |
|----------------------|-------|------------|----------|--------|
|                      |       | (16.7%)    | (0.0%)   | (8.3%) |
| Osteoporosis         | 10    | 0          |          | 10     |
| Osteopenia           | 37    | 22         |          | 59     |
| Normal               | 13    | 38         |          | 51     |
| Total                | 60    | 60         |          | 120    |

Chi-Square Tests

| Value | Df | p-value | Association is |
|-------|----|---------|----------------|
| 26.068| 2  | 2.18E-06| Significant    |

Tables (6, 7 & 8) show that COPD patients are more osteoporotic compared to control group and that, their difference is statistically significant. Among COPD patients osteoporosis is more common in AP spine (56.7%, T-score -2.50) as opposed to dual femur (33.3%, T-score -2.05) & whole body (16.7%).

Table 9: Distribution of COPD patients in relation to severity of COPD (Gold Staging)

| GOLD Staging   | No. (%) |
|----------------|---------|
| Moderate       | 27(45%) |
| Severe         | 24(40%) |
| Very severe    | 9(15%)  |
| Total          | 60(100%)|

Table 10: Association between Severity of COPD (Gold staging) and Lumbar spine Bone mineral density.

| GOLD Staging | BMD t- score (Lumbar spine) | Total |
|--------------|-----------------------------|-------|
|              | Osteoporosis | Osteopenia | Normal |       |
| Moderate     | 4 (14.8%)    | 22 (81.5%) | 1 (3.7%) | 27 (100.0%) |
| Severe       | 22 (91.7%)   | 2 (8.3%)   | 0 (0.0%) | 24 (100.0%) |
| Very severe  | 8 (88.9%)    | 1 (11.1%)  | 0 (0.0%) | 9 (100.0%)  |
| Total        | 34 (56.7%)   | 25 (41.7%) | 1 (1.7%) | 60 (100.0%) |

| Value | Df | p-value | Association is |
|-------|----|---------|----------------|
| Chi- Square Test | 35.094 | 4 | 4.44E-07 | Significant |
| Pearson Chi-Square | 0.000 | 1 | 1.000 | Not significant |
Table 11: Association between Severity of COPD (Gold staging) Dual Femur neck Bone mineral density.

| GOLD Staging | BMD t-score (Dual femur neck) | Total |
|--------------|-------------------------------|-------|
|              | Osteoporosis | Osteopenia | Normal |       |
| Moderate     | 2 (7.4%)     | 18 (66.7%) | 7 (25.9%) | 27 (100.0%) |
| Severe       | 13 (54.2%)   | 11 (45.8%) | 0 (0.0%) | 24 (100.0%) |
| Very severe  | 5 (55.6%)    | 4 (44.4%)  | 0 (0.0%) | 9 (100.0%)  |
| Total        | 20 (33.3%)   | 33 (55.0%) | 7 (11.7%) | 60 (100.0%) |

|                       | Value | df | p-value | Association is- |
|-----------------------|-------|----|---------|-----------------|
| Pearson Chi-Square    | 19.676| 4  | 0.0005  | Significant     |
| Chi-Square test       | 0.384 | 1  | 0.536   | Not significant |

Table 12: Association between Severity of COPD (Gold staging) and Whole Body Bone mineral density(T-score).

| GOLD Staging | T-score (Whole body) | Total |
|--------------|----------------------|-------|
|              | Osteoporosis | Osteopenia | Normal |       |
| Moderate     | 0 (0.0%)     | 16 (59.3%) | 11 (40.7%) | 27 (100.0%) |
| Severe       | 8 (33.3%)    | 15 (62.5%) | 1 (4.2%) | 24 (100.0%) |
| Very severe  | 2 (22.2%)    | 6 (66.7%)  | 1 (11.1%) | 9 (100.0%)  |
| Total        | 10 (16.7%)   | 37 (61.7%) | 13 (21.7%) | 60 (100.0%) |

|               | Value | Df | p-value | Association is- |
|---------------|-------|----|---------|-----------------|
| Chi-Square    | 17.120| 4  | 0.00183 | Significant     |
| Pearson Chi-Square | 10.709| 2  | 0.005   | Significant     |

The above tables (10,11,12) show, that percentage of osteoporosis & osteopenia increases as the severity of COPD increases. This association was statistically significant only for Whole Body bone densitometry (p-value 0.005).

**DISCUSSION**

The study population, both the cases and control were age and sex matched.

Out of 37/60(61.66%) COPD patients, 56% of females and 65.71% of males had osteoporosis. 22/60(36.66%) COPD patients had osteopenia. As opposed, only 11.6% and 68.3% control group patients were diagnosed to have osteoporosis and osteopenia respectively. A similar study done by Sin DD, et al. showed prevalence of osteoporosis to be 9%-69% in COPD patients versus 0%-13% in healthy individuals. [10]

In our study we observed that osteoporosis was more common in males than female patients. Osteoporosis was diagnosed in 57.1% of men using measurements of the Lumbar spine, 42.9% using the dual femur, and 22.9% using the total...
body. As opposed to in females it was 56%, 20% and 8% respectively. However, this difference was not statistically significant.

Subjects were grouped according to the WHO criteria, and diagnosed as osteoporotic, osteopenic, or normal bone mass according to T-score for BMD. Thus, in our study 23/35(65.71%) males and 14/25(56%) females were diagnosed to have osteoporosis.

A study done by J.M. Vaquero-Barrios, et al. supports the results of our study. In their study 88.2% of men and 69.2% of women had osteoporosis.

According to WHO, female gender was not a significant risk factor for osteoporosis although in the overall population women are at increased risk of osteoporosis as compared to their male peers. Also a study by Jorgensen NR, et al., said that incidence of osteoporosis is higher in women than in men, and it is to be expected that women with COPD would be even more susceptible to develop osteoporosis than women with normal lung function.

In our study, osteoporosis & osteopenia were more in COPD patients as compared to the control group.

Osteoporosis of Lumbar spine was 56.7% and osteopenia 41.7% among COPD patients, compared to 8.3% and 63.3% respectively in control group.

The median BMD T-score (Lumbar spine) for COPD patients was also lower than control group patients. -1.50 and -0.20 respectively.

Subjects were grouped according to the WHO criteria, and diagnosed as osteoporotic, osteopenic, or normal bone mass according to T-score for BMD. Thus, in our study 23/35(65.71%) males and 14/25(56%) females were diagnosed to have osteoporosis.

The median BMD T-score (Lumbar spine) for COPD patients was also lower than control group patients. -1.50 and -0.20 respectively.

Thus, 65.71% of COPD patients had osteoporosis and 11.6% of control group patients had osteoporosis. Also COPD patients were more prone to lumbar spine osteoporosis than that of dual femur or whole body. In accordance to our results a study done by Jorgensen NR, et al., also showed that in COPD patients lumbar spine was more osteoporotic.

Comparison studies done by Bolton et al, Sabit et al and Dimai et al in an age-matched control group of healthy subjects in COPD, the prevalence of osteoporosis is assumed to be two- to five-fold higher than in age-matched subjects without airflow obstruction. The prevalence of osteoporosis in COPD was increased compared with the healthy subjects (overall mean prevalence of osteoporosis of 31.7% in COPD versus 5.8% in healthy subjects, p<0.001). In another study done by Jorgensen NR, et al., 44.8% were osteoporotic, and 22.4% were osteopenic and 25.9% had normal bone mass.

**Moderate grade COPD patients with a mean postbronchodilator-FEV1**

of 0.57 (±0.05) and mean duration from diagnosis of COPD was 6 years (min -1year, max -20 years) had T-score of median -1.80 (-3.20, 0.60) of Lumbar spine, median -1.60 (-3.30, 1.50) of dual femur and median -1.10 (-2.30, 1.60) of whole Body.

Severe grade COPD patients with a mean postbronchodilator-FEV1 0.43 (±0.04) and mean duration from diagnosis of COPD was 9 years (min -2years, max -30 years) had T-score of median -2.75 (-4.50, -1.90) of Lumbar spine,
median -2.55 (-4.50, -1.20) of Dual femur and median -2.10 (-4.0, -0.50) of whole body.

Very Severe grade COPD with a mean postbronchodilator-FEV1 0.30 (0.04), and mean duration from diagnosis of COPD was 8 years (min -1years, max -15years) had T-score of median -2.50 (-3.20, -1.90) of Lumbar spine, median -2.0 (-3.40, -1.10) of dual femur and median -1.40(-3.30,0.80) of whole body.
So, Severe and Very severe COPD patients had a lesser median value of T-score compared to moderate COPD patients.

We found statistically significant bivariate correlation between whole body T-score and severity of COPD. Also there was statistically significant association between the time from diagnosis of COPD and Dual femur (neck) T-score, when compared to COPD patient with normal BMD. In our study osteoporosis was diagnosed in 6/27 (22.2%) moderate COPD patients, 25/26(96%) severe COPD patients and 6/7 (85.7%) very severe COPD patients.
These results were in agreement with Iqbal et al., who found that, in COPD group who had osteoporosis BMD decreases in linear pattern with the decrease of FEV1%. [12] Also, these results were in agreement with the results of the cross sectional study carried by Jorgensen et al. who found that, BMD had direct relation with FEV1% in COPD patients who had osteoporosis. [5]
Also a study by Sin et al., revealed that risk of osteopenia increases by 30% in moderate COPD and by 70% in severe COPD more than normal personnel, and the risk of osteoporosis increases by 2.1 fold in moderate COPD and by 2.8 fold in severe COPD more than normal personnel. [12]

CONCLUSIONS
In conclusion, we found that COPD patients are more osteoporotic when compared to age –sex matched control group patients and also the risk of osteoporosis increases with the severity of COPD. However we suggest that the similar study with larger sample size with periodic following up of the cases is necessary for endorsing our findings.

Based upon the findings of the present study we recommend that there should be periodic active screening of the COPD patients for osteoporosis by BMD and these patients should also receive calcium and vitamin D supplements.

ACKNOWLEDGEMENT
Dr Prabhudesai Pralhad as a guide, Department of Pulmonary Medicine and DEXA scan, Radiology Department, Lilavati hospital, Mumbai

REFERENCES
1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013 Available from: Global Initiative for Chronic Obstructive lung Disease (GOLD), Web site: www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf
2. World Health Organization. Burden of COPD. Available from: http://www.who.int/respiratory/copd/burden/en/index.html
3. Papaioannou A, Parkinson W, FerkoN, et al (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. OsteoporosInt 2003; 14(11):913–917.
4. Jorgensen NR, Schwarz P, HolmeI. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease-A cross sectional study. Respir Med 2007; 101 (1):177-85.
5. Graat-Verboom L, E.F.M Wouters, F.M.J.M Smeenk, et al. Current status of research on osteoporosis in COPD: a systemic review. EurRespir J 2009; 341:209-18
6. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56:279–84.
7. Praet JP, Peretz A, Rozenberg S. Risk of osteoporosis in men with chronic bronchitis. Osteoporos Int 1992; 2:257–61.

8. Burge PS, Calverley PM, Jones PW. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320:1297–303.

9. Richy F, Bousquet J, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003; 14(3):179-190.

10. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: A pilot study. BMC Pulm Med. 2007; 7:13.

11. Vaquero-Barrios JM, Arenas-de Larriva MS, Redel-Montero J, et al. Bone mineral density in patients with chronic obstructive pulmonary disease who are candidates for lung transplant. Transplant Proc. 2010 Oct;42(8):3020-2.

12. WHO Scientific Group on the Prevention and management of osteoporosis: report of a WHO scientific group, 2007.